section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: pruritus, rash, sweating, urticaria.

EENT: acute iritis, pharyngitis, rhinitis, sinusitis.

Endo: fat redistribution, hyperglycemia.

F and E: dehydration.

GI: diarrhea, anorexia, dyspepsia, epigastric pain, flatulence, GI bleeding, hepatitis, liver enzymes, nausea, oral ulcerations, pancreatitis, vomiting.

GU: nephrolithiasis, sexual dysfunction.

Hemat: anemia, leukopenia, thrombocytopenia.

Metab: hyperlipidemia, hyperuricemia.

MS: arthralgia, arthritis, back pain, myalgia, myopathy.

Neuro: anxiety, depression, dizziness, drowsiness, emotional lability, headache, hyperkinesia, insomnia, malaise, migraines, myasthenia, paresthesia, SEIZURES, sleep disorders, SUICIDAL IDEATION, weakness.

Resp: dyspnea.
Misc: allergic reactions, fever, immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Availability

Route/Dosage

see Calculator

US Brand Names

Viracept

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: protease inhibitors

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed to tissues.

Protein Binding: >98%.

Metabolism/Excretion: Primarily metabolized in the liver via the CYP2C19 and CYP3A4 isoenzymes; the CYP2C19 isoenzyme exhibits genetic polymorphism; 15–20% of Asian patients and 3–5% of Caucasian and Black patients may be poor metabolizers and may have significantly nelfinavir concentrations and an risk of adverse effects. Excreted in feces as metabolites (78%) or unchanged drug (22%); minimal renal excretion.

Half-life: 3.5–5 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid2–4 hr8 hr

Patient/Family Teaching

Pronunciation

nell-FINN-a-veer